Leap Therapeutics (LPTX) Stock Forecast, Price Target & Predictions
LPTX Stock Forecast
Leap Therapeutics stock forecast is as follows: an average price target of $5.50 (represents a 113.18% upside from LPTX’s last price of $2.58) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LPTX Price Target
The average price target for Leap Therapeutics (LPTX) is $5.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.50 to $5.50. This represents a potential 113.18% upside from LPTX's last price of $2.58.
LPTX Analyst Ratings
According to 3 Wall Street analysts, Leap Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LPTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Leap Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $5.50 | $2.83 | 94.35% | 113.18% |
The latest Leap Therapeutics stock forecast, released on May 14, 2024 by Swayampakula Ramakanth from H.C. Wainwright, set a price target of $5.50, which represents a 94.35% increase from the stock price at the time of the forecast ($2.83), and a 113.18% increase from LPTX last price ($2.58).
Leap Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.50 |
| Last Closing Price | $2.58 | $2.58 | $2.58 |
| Upside/Downside | -100.00% | -100.00% | 113.18% |
In the current month, the average price target of Leap Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Leap Therapeutics's last price of $2.58. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 14, 2023 | Raymond James | Outperform | Outperform | Hold |
| Nov 11, 2022 | Raymond James | Outperform | Outperform | Hold |
Leap Therapeutics's last stock rating was published by Rodman & Renshaw on Jun 28, 2024. The company Initialise its LPTX rating from "null" to "Buy".
Leap Therapeutics Financial Forecast
Leap Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $375.00 | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K | $375.00K |
| Avg Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| High Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| Low Forecast | $11.73M | $9.67M | $7.60M | $5.53M | - | - | - | $1.50M | $188.75K | $386.00K | $1.44M | $305.00K | $258.33K | $391.67K | $200.00K | $1.30M | $3.00M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.26% | 1.23% | 1.45% | 0.96% | 1.88% | 0.29% | 0.13% |
Leap Therapeutics's average Quarter revenue forecast for Mar 22 based on 1 analysts is $188.75K, with a low forecast of $188.75K, and a high forecast of $188.75K. LPTX's average Quarter revenue forecast represents a 50233.33% increase compared to the company's last Quarter revenue of $375.00 (Dec 21).
Leap Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-12.65M | $-10.59M | $-10.89M | $-11.12M | $-9.60M | $-9.02M | $-7.11M | $-6.94M | $-6.37M | $-7.02M |
| Avg Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-11.64M | $77.20K | $287.00K | $61.00K | $-8.20M | $78.33K | $40.00K | $260.00K | $-4.31M |
| High Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-9.32M | $77.20K | $287.00K | $61.00K | $-6.56M | $78.33K | $40.00K | $260.00K | $-3.45M |
| Low Forecast | $2.35M | $1.93M | $1.52M | $1.11M | - | - | - | $300.00K | $-13.97M | $77.20K | $287.00K | $61.00K | $-9.84M | $78.33K | $40.00K | $260.00K | $-5.18M |
| Surprise % | - | - | - | - | - | - | - | -42.16% | 0.91% | -141.09% | -38.76% | -157.35% | 1.10% | -90.80% | -173.53% | -24.50% | 1.63% |
undefined analysts predict LPTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Leap Therapeutics's previous annual EBITDA (undefined) of $NaN.
Leap Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-12.10M | $-10.14M | $-10.79M | $-11.14M | $-9.53M | $-9.13M | $-6.71M | $-7.06M | $-6.52M | $-7.23M |
| Avg Forecast | $-12.57M | $-13.50M | $-14.01M | $-14.73M | $-16.65M | $-20.36M | $-16.43M | $-45.33M | $-11.41M | $-43.03M | $-43.82M | $-48.51M | $-8.30M | $-34.43M | $-50.08M | $-70.42M | $-4.44M |
| High Forecast | $-12.57M | $-13.50M | $-14.01M | $-13.54M | $-15.37M | $-20.36M | $-16.43M | $-45.33M | $-9.13M | $-43.03M | $-43.82M | $-48.51M | $-6.64M | $-34.43M | $-50.08M | $-70.42M | $-3.56M |
| Low Forecast | $-12.57M | $-13.50M | $-14.01M | $-16.33M | $-17.50M | $-20.36M | $-16.43M | $-45.33M | $-13.70M | $-43.03M | $-43.82M | $-48.51M | $-9.96M | $-34.43M | $-50.08M | $-70.42M | $-5.33M |
| Surprise % | - | - | - | - | - | - | - | 0.27% | 0.89% | 0.25% | 0.25% | 0.20% | 1.10% | 0.19% | 0.14% | 0.09% | 1.63% |
Leap Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LPTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Leap Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $2.91M | $2.85M | $2.79M | $2.44M | $2.79M | $2.74M | $2.54M | $2.29M | $2.49M | $2.07M |
| Avg Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.27M |
| High Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.53M |
| Low Forecast | $38.93M | $32.07M | $25.21M | $18.36M | - | - | - | $4.98M | $626.20K | $1.28M | $4.76M | $1.01M | $857.04K | $1.30M | $663.52K | $4.31M | $1.02M |
| Surprise % | - | - | - | - | - | - | - | 0.58% | 4.55% | 2.18% | 0.51% | 2.76% | 3.20% | 1.95% | 3.45% | 0.58% | 1.63% |
Leap Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to LPTX last annual SG&A of $2.91M (Dec 22).
Leap Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.11 | $-0.09 | $-0.10 | $-0.14 | $-0.12 | $-0.12 | $-0.09 | $-0.09 | $-0.12 | $-0.23 |
| Avg Forecast | $-0.30 | $-0.33 | $-0.34 | $-0.36 | $-0.40 | $-0.49 | $-0.42 | $-1.10 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| High Forecast | $-0.30 | $-0.33 | $-0.34 | $-0.33 | $-0.37 | $-0.49 | $-0.42 | $-1.10 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| Low Forecast | $-0.30 | $-0.33 | $-0.34 | $-0.40 | $-0.42 | $-0.49 | $-0.42 | $-1.10 | $-1.00 | $-1.10 | $-1.12 | $-1.24 | $-1.06 | $-0.88 | $-1.28 | $-1.80 | $-2.45 |
| Surprise % | - | - | - | - | - | - | - | 0.10% | 0.09% | 0.09% | 0.13% | 0.10% | 0.11% | 0.10% | 0.07% | 0.07% | 0.09% |
According to undefined Wall Street analysts, Leap Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LPTX previous annual EPS of $NaN (undefined).
Leap Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
| PDSB | PDS Bio | $2.20 | $9.00 | 309.09% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| LPTX | Leap Therapeutics | $2.58 | $5.50 | 113.18% | Buy |
| MREO | Mereo BioPharma Group | $3.68 | $6.75 | 83.42% | Buy |
| HOOK | HOOKIPA Pharma | $2.30 | $3.00 | 30.43% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |